Wolfe Research upgraded Argenx (ARGX) to Outperform from Peer Perform with a $697 price target Now through 2025, there will be few exciting catalysts in favor of Argenx – aside from myositis and PFS – but those in and of themselves are “huge”, the analyst tells investors in a research note. Wolfe sees positive earnings results from argenx to drive the stock in 2025, especially given the company’s consistent history of beating revenue, while also noting that its operating margins are “trending positive”.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARGX:
- Argenx upgraded to Outperform from Peer Perform at Wolfe Research
- Argenx, Zai Lab announce approval of VYVGART Hytrulo in China
- Zai Lab, Argenx announce China NMPA approval for Vyvgart Hytrulo sBLA
- Scotiabank upgrades Argenx on Vyvgart upside, pipeline optionality
- Argenx upgraded to Outperform from Sector Perform at Scotiabank
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
